• Heinz Ludwig, Rayko Evstatiev, Gabriela Kornek, Matti Aapro, Thomas Bauernhofer, Veronika Buxhofer-Ausch, Michael Fridrik, Dietmar Geissler, Klaus Geissler, Heinz Gisslinger, Elisabeth Koller, Gerhard Kopetzky, Alois Lang, Holger Rumpold, Michael Steurer, Houman Kamali, and Hartmut Link.
• c/o 1. Medizinische Abteilung, Zentrum für Onkologie, Wilhelminen-Krebsforschungsinstitut, Wilhelminenspital, Montleartstraße 37, 1160, Wien, Austria. heinz.ludwig@aon.at.
• Wien. Klin. Wochenschr. 2015 Dec 1; 127 (23-24): 907919907-19.

AbstractIron deficiency and iron deficiency-associated anemia are common complications in cancer patients. Most iron deficient cancer patients present with functional iron deficiency (FID), a status with adequate storage iron, but insufficient iron supply for erythroblasts and other iron dependent tissues. FID is the consequence of the cancer-associated cytokine release, while in absolute iron deficiency iron stores are depleted resulting in similar but often more severe symptoms of insufficient iron supply. Here we present a short review on the epidemiology, pathophysiology, diagnosis, clinical symptoms, and treatment of iron deficiency in cancer patients. Special emphasis is given to intravenous iron supplementation and on the benefits and limitations of different formulations. Based on these considerations and recommendations from current international guidelines we developed recommendations for clinical practice and classified the level of evidence and grade of recommendation according to the principles of evidence-based medicine.

26 keywords...

hide…